Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
REN001
OnKure Therapeutics
Primary Mitochondrial Myopathy
2 trials -
Mavodelpar
OnKure Therapeutics
Primary Mitochondrial Myopathy
1 trial -
OKI-179 + binimetinib
OnKure Therapeutics
RAS Mutation
1 trial -
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
OnKure Therapeutics
Advanced Solid Tumors, Advanced Breast Cancer
1 trial -
Low Dose REN001
OnKure Therapeutics
Fatty Acid Oxidation Disorders
1 trial -
OKI-179
OnKure Therapeutics
Advanced Solid Tumors
1 trial -
OKI-219
OnKure Therapeutics
Advanced Cancer
1 trial -
REN001
OnKure Therapeutics
McArdle Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources